Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sinovac Gains GMP Certification from SFDA | Contract Pharma
Breaking News

Sinovac Gains GMP Certification from SFDA

Will commence mumps vaccine production

Sinovac Biotech Ltd., a China-based vaccine manufacturer, has received GMP certification from the China State Food and Drug Administration (SFDA) for mumps vaccine production plant at its Sinovac Dalian facility. The company obtained the production license from the SFDA for its mumps vaccine in December 2011. Sinovac anticipates commercial production of the vaccine in 3Q12 and is on track to launch the vaccine in China following the batch release process.
 
Mr. Weidong Yin, chairman, president and chief executive of Sinovac, said, “Obtaining GMP certification for the mumps vaccine production facility is a significant milestone as we advance our development pipeline and expand our portfolio of commercialized vaccines. We are poised to leverage our established sales and marketing team and distribution network that covers over 1,000 clients at Centers of Disease Control and Points of Vaccination across China. The commercialization of mumps vaccine is a testament to our capabilities to develop additional live attenuated vaccines. Commercial production of the mumps vaccine will commence immediately and we anticipate launching the vaccine either later this year or early next year following the batch release process.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters